Vascular dementia innovation three periods of clinical Chinese medicine in Australia start storing pharmaceutical industry to participate in the research and development

Source: hebei news

The 2015-12-08 22:40:16

Is expected to become the first in the innovation of registered overseas listing of Chinese medicine, the sunway pharmaceutical group in our province to participate in the research and development

Hebei newswise - (correspondent ZhenYu The news reporter Ma Yanming) recently, the hebei daily, by storing pharmaceutical group co., LTD., China academy of traditional Chinese medicine xiyuan hospital, university of western Sydney, Australia, joint research and development innovation as a component of the treatment of vascular dementia medicine plug collaterals tong capsule launched phase iii trial in Australia. It is reported, this is the first to enter the third phase of clinical trial components of traditional Chinese medicine. The traditional Chinese medicine (TCM) phase iii trial will be carried out in China, Australia and at the same time, it will take about two years time, is expected to become the first in the innovation of registered overseas listing of Chinese traditional medicine.

Vascular dementia in the elderly is one of the main reasons for the physical and mental health disorders, is the second largest after alzheimer's disease dementia. Plug collaterals capsule is ministry of science and technology "major drug discovery" science and technology major projects, and in 2009 won the state food and drug administration license of the clinical trial is the first domestic approved to enter clinical research phase of the components of traditional Chinese medicine. In 2012, China academy of traditional Chinese medicine xiyuan hospital and university of western Sydney Australia NICM countries complementary medicine research institute, the sunway pharmaceutical group co., LTD., the three parties signed plug collaterals capsule international multicenter synchronization clinical research protocols, aimed at the domestic and foreign research, synchronization, synchronizing registration, the first was the first modern Chinese medicine international industry-university-institute cooperation.

Australia is the first in the form of legislation to admit the legal status of Chinese medicine in the west. At the same time, Australia is an international drug supervisory cooperation scheme (PIC/S), and the European Union more than 20 countries signed a mutual recognition agreement, both sides through the Australian federal drug administration (fda) certification of traditional Chinese medicine, can enter the European Union, South Korea, South Africa, Malaysia, etc.

In recent years, along with the medicine pattern transformation, the unique medical and health value of traditional Chinese medicine increasingly brought to the attention of the world. But the traditional Chinese medicine due to unclear material foundation, mechanism is not clear, the internationalization process is not smooth. At present, the Chinese traditional medicine the main way to enter foreign markets such as health care products, nutritional agent. Compared with the traditional Chinese medicine, component from traditional Chinese medicine, but its chemical composition, mechanism clearly clear and consistent with the clinical effect of quality control. Plug complex capsules at the end of the third phase of clinical trial, is expected to be in Australia as a drug registration and officially listed. Industry experts believe that this to speed up the internationalization of traditional Chinese medicine (TCM) is of great significance.